Antimycobacterial activity of new N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives

  • Bioorg Med Chem Lett. 2016 Jul 15;26(14):3287-3290. doi: 10.1016/j.bmcl.2016.05.053.
Daniele Zampieri  1 ,  Maria Grazia Mamolo  2 ,  Luciano Vio  2 ,  Maurizio Romano  3 ,  Nataša Skoko  4 ,  Marco Baralle  4 ,  Valentina Pau  5 ,  Alessandro De Logu  5
Affiliations
  • 1. Department of Chemistry and Pharmaceutical Sciences, Piazzale Europa 1, University of Trieste, 34127 Trieste, Italy. Electronic address: [email protected].
  • 2. Department of Chemistry and Pharmaceutical Sciences, Piazzale Europa 1, University of Trieste, 34127 Trieste, Italy.
  • 3. Department of Life Sciences, Via Valerio 28/1, University of Trieste, 34127 Trieste, Italy.
  • 4. ICGEB, International Centre for Genetic Engeneering and Biootechnology, Padriciano 99, 34149 Trieste, Italy.
  • 5. Department of Life and Enviromental Sciences, Via Porcell 4, University of Cagliari, 09124 Cagliari, Italy.
PMID: 27241693 DOI: 10.1016/j.bmcl.2016.05.053
Abstract

N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives were design, synthesized and tested for their in vitro antimycobacterial activity. The new compounds showed a moderate antimycobacterial activity against the tested strain of Mycobacterium tuberculosis H37Ra and a significant antimycobacterial activity against several mycobacteria Other than tuberculosis strains.

Keywords
Antimycobacterial activity; Mycobacteria other than tuberculosis (MOTT); Pyridine-2-carboxamidrazone derivatives.